Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › trastuzumab

trastuzumab

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of trastuzumab

197 trials tracked of trastuzumab: 57 in phase 3 or 4 and 33 with published results. The most-cited published study has 2781 citations.

197Trials tracked
57Phase 3 & 4
0Recruiting
33With published results
Phase distribution
Phase 4 4 Phase 3 53 Phase 2 124 Phase 1 11 Other / NA 5
  1. Phase 3 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed · 2,781 cited
  2. Phase 3 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Completed · 2,627 cited
  3. Phase 3 Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer Completed · 1,513 cited
  4. Phase 3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Completed · 693 cited
  5. Phase 3 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 534 cited
  6. Phase 3 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer Completed · 492 cited
Show 44 more trials
  1. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 480 cited
  2. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 421 cited
  3. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 352 cited
  4. Phase 3 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Completed · 351 cited
  5. Phase 3 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Completed · 307 cited
  6. Phase 3 Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel Completed · 193 cited
  7. Phase 3 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Completed · 166 cited
  8. Phase 3 Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. Completed · 145 cited
  9. Phase 3 Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer Completed · 123 cited
  10. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer Completed · 114 cited
  11. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  12. Phase 3 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Completed · 104 cited
  13. Phase 3 A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer Completed · 100 cited
  14. Phase 3 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Completed · 99 cited
  15. Phase 3 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer Completed · 98 cited
  16. Phase 3 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Completed · 64 cited
  17. Phase 3 A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) Completed · 60 cited
  18. Phase 3 A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Completed · 49 cited
  19. Phase 3 A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 46 cited
  20. Phase 3 A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC) Completed · 43 cited
  21. Phase 3 Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer Completed · 37 cited
  22. Phase 3 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Completed · 31 cited
  23. Phase 3 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Completed · 28 cited
  24. Phase 3 A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer Completed · 26 cited
  25. Phase 3 A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Completed · 20 cited
  26. Phase 3 A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients Completed · 17 cited
  27. Phase 3 A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 12 cited
  28. Phase 4 A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment Completed
  29. Phase 4 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer Completed
  30. Phase 4 Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen Completed
  31. Phase 4 XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Completed
  32. Phase 3 A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) Completed
  33. Phase 3 Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer Completed
  34. Phase 3 Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 Completed
  35. Phase 3 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Completed
  36. Phase 3 Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer Completed
  37. Phase 3 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer Completed
  38. Phase 3 Demonstrate Efficacy and Safety of Metastatic Breast Cancer Completed
  39. Phase 3 Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer Completed
  40. Phase 3 A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer Completed
  41. Phase 3 Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery Completed
  42. Phase 3 THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. Completed
  43. Phase 3 Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Completed
  44. Phase 3 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 197 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer
Rheumatology Sys. Review
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer Case shows new drug combo may help breast cancer patient
This case report and literature review describes a patient with HER2+/HR+ breast cancer who achieved total pathological complete response af…
A woman with HER2-positive breast cancer achieved complete response after switching to a pyrotinib-based regimen when standard therapy faile…
Frontiers Jul 25, 2026
Paclitaxel arm achieves 56.4% pathologic complete response compared to 23.7% with endocrine therapy
Oncology RCT
Paclitaxel arm achieves 56.4% pathologic complete response compared to 23.7% with endocrine therapy Trial shows chemotherapy helps shrink early breast cancer more effectively
This Phase II multicenter randomized trial evaluated neoadjuvant trastuzumab and pertuzumab combined with either endocrine therapy or paclit…
A new trial compares using standard chemotherapy versus hormone therapy to shrink tumors before surgery in patients with HER2-positive breas…
Jul 20, 2026
Multidisciplinary management of mixed adenoneuroendocrine carcinoma of the gallbladder involves surgery and adjuvant chemotherapy
Oncology Meta-analysis
Multidisciplinary management of mixed adenoneuroendocrine carcinoma of the gallbladder involves surgery and adjuvant chemotherapy Rare gallbladder cancer type shows specific genetic markers and traits
This case report and literature review describes the clinical management of a patient with mixed adenoneuroendocrine carcinoma of the gallbl…
A rare form of gallbladder cancer, known as GB-MANEC, was identified in a patient who underwent surgery and chemotherapy with no recurrence …
Frontiers Jun 30, 2026
DeSTIL-positive HER2+ breast cancer patients show HR 0.09 for event-free survival with trastuzumab
Oncology RCT
DeSTIL-positive HER2+ breast cancer patients show HR 0.09 for event-free survival with trastuzumab Trial Shows DeSTIL Signature Identifies Patients Benefiting From Trastuzumab
This Phase III randomized clinical trial evaluated the DeSTIL signature in a cohort of 221 validation patients and 250 training patients wit…
A new genetic marker called DeSTIL helps identify which HER2-positive breast cancer patients may see better outcomes when treated with trast…
Jun 18, 2026
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer
Oncology RCT
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer Trial shows omitting carboplatin maintains success in breast cancer
This Phase III randomized controlled trial of 766 women with untreated, stage II and III, HER2-positive invasive breast cancer found that th…
A new clinical trial shows that removing one specific drug can lower severe side effects while maintaining high success rates for certain br…
Jun 12, 2026
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC
Oncology RCT
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC Trial shows Tucatinib improves progression-free survival for metastatic breast cancer
This Phase III randomized controlled trial of 654 patients with HER2+ metastatic breast cancer found that adding tucatinib to trastuzumab an…
Adding tucatinib to a standard two-drug combination may help patients with HER2+ metastatic breast cancer live longer without their disease …
Jun 12, 2026
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
OB/GYN & Women's Health RCT
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Jun 1, 2026
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Oncology Sys. Review
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Frontiers May 8, 2026
Trastuzumab emtansine and trastuzumab deruxtecan use in three patients with ERBB2-amplified rare tumors
Oncology Cohort
Trastuzumab emtansine and trastuzumab deruxtecan use in three patients with ERBB2-amplified rare tumors Rare tumors respond to targeted antibody drug treatments
This retrospective case series evaluated three patients with ERBB2-amplified rare tumors, including periampullary, salivary duct, and poorly…
Three patients with rare, aggressive cancers saw significant tumor shrinkage after receiving targeted antibody drug therapies.
Frontiers Apr 30, 2026
FDA Approves Perjeta (pertuzumab) for HER2-Positive Breast Cancer
Oncology FDA Approval
FDA Approves Perjeta (pertuzumab) for HER2-Positive Breast Cancer FDA approves new drug Perjeta for HER2-positive breast cancer
The FDA approved Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer an…
The FDA approved Perjeta (pertuzumab) for HER2-positive breast cancer.
FDA Apr 29, 2026
QDB method shows higher consistency than IHC for HER2 assessment in invasive breast cancer
Oncology Cohort
QDB method shows higher consistency than IHC for HER2 assessment in invasive breast cancer New Test Finds Hidden Breast Cancer Targets
This observational cohort study compared a Quantitative Dot Blot (QDB) method to immunohistochemistry (IHC) for HER2 assessment in patients …
Some women told their breast cancer lacks a key target may actually benefit from powerful drugs — a new test can finally tell the difference…
Frontiers Apr 27, 2026
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients
Oncology Cohort
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients Many Breast Cancer Patients Can Avoid Heart Damage — If Doctors Know the Warning Signs
This retrospective analysis of 298 HER2-positive breast cancer patients assessed trastuzumab-induced cardiotoxicity.
This could help doctors protect patients’ hearts before cancer therapy even begins.
Frontiers Apr 23, 2026

All trastuzumab Articles